Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.54 |
| ▸ | MME | P08473 | 6/20 | 0.54 |
| ▸ | CPA1 | P15085 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | IL1RN | P18510 | 1/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195269 | 0.96 | MME (0.50) | ACEMMECPA1ACE2ENPEP | |
| SCHEMBL30123042 | 0.93 | MME (0.58) | ACEMMECPA1ACE2ENPEP | |
| SCHEMBL9822772 | 0.93 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL21828686 | 0.93 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL9822750 | 0.93 | ACE (0.61) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31500682 | 0.92 | ENPEP (0.54) | ACEMMECPA1ACE2ENPEP | |
| SCHEMBL29968694 | 0.92 | BACE1 (0.54) | ACEMMEENPEP | |
| SCHEMBL31613781 | 0.91 | NAALAD2 (0.62) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29370021 | 0.91 | NAALAD2 (0.62) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30400950 | 0.90 | MME (0.53) | ACEMMECPA1ACE2NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113528552-B | Gene combination for synergetic catalysis of tea tree ester type catechin biosynthesis and application thereof | 安徽农业大学 | 2024-01-09 | — | — | CN | disclosed |
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. | 2022-09-15 | — | — | US | disclosed |
| EP-3976594-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | The Schepens Eye Research Institute, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114206849-A | Therapeutic methods for treating non-infectious ocular immunoinflammatory disorders | 斯格本斯眼科研究所有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288028-A1 | A THERAPEUTIC APPROACH FOR TREATING NON-INFECTIOUS OCULAR IMMUNOINFLAMMATORY DISORDERS | MSR1, LTB4R2, LTB4R | ACE 643/4885MME 685/4885CPA1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.